You are here: Industry Insights > Treatment

News List

Stimulant Treatment Has Strong Protective Effect in ADHD drugs
July 30, 2019
For youth with attention-deficit/hyperactivity disorder (ADHD), stimulants have strong protective effects on functional outcomes...
Health Tip: Understanding Exposure Therapy drugs
July 29, 2019
Exposure therapy is a psychological treatment developed to help people confront their fears, says the American Psychological Association (APA).
FDA Approves New Severe Hypoglycemia Treatment americanpharmaceuticalreview
July 26, 2019
The U.S. Food and Drug Administration (FDA) approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection.
Regulus Therapeutics Announces RGLS4326 Program Hold americanpharmaceuticalreview
July 25, 2019
Regulus Therapeutics announced a program update for RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company has been working with the United States Food and Drug Administration (FDA) since July 2018 ...
Warning issued to company for using unfounded CBD treatment claims europeanpharmaceuticalreview
July 25, 2019
FDA issues warning to a company that claimed its CBD products can be used to treat cancer and Alzheimer’s disease.
Opiant Pharmaceuticals, Sanofi to Manufacture Acute Cannabinoid Overdose Treatment contractpharma
July 25, 2019
Opiant’s drinabant, selective cannabinoid receptor antagonist, could be first approved treatment for ACO.
La Jolla Pharma Receives Orphan Designation for Malaria Treatment contractpharma
July 24, 2019
LJPC-0118, artesunate, demonstrated to be superior to quinine in reducing mortality in patients with falciparum malaria infection.
APB-102 Receives Orphan Drug Designation for Genetic SOD1 ALS Treatment americanpharmaceuticalreview
July 23, 2019
Apic Bio announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to APB-102, a gene therapy soon to be in clinical development for the treatment of genetic SOD1 amyotrophic lateral sclerosis (ALS).
Complete response letter given to ALS treatment for API concern europeanpharmaceuticalreview
July 23, 2019
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.
FDA Approves Treatment for Complicated Urinary Tract, Complicated Intra-Abdominal Infections americanpharmaceuticalreview
July 19, 2019
The U.S. Food and Drug Administration (FDA) has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page